X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TCRR

Closed

Tcr2 Therapeutics Inc

1.48
-0.09 (-5.73%)
Last Update: 01 Jun 2023 16:30:00
Yesterday: 1.57
Day's Range: 1.48 - 1.48
Send
When Written:
 
1.545
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on the development of novel T cell therapies for cancer patients. The company's proprietary TRuC™ (TCR Fusion Construct) platform enables the engineering of T cells with enhanced specificity and potency against a range of solid tumors. TCR2's lead product candidate, TC-210, is a first-in-class TRuC-T cell therapy that is being evaluated in Phase 1/2 clinical trials for the treatment of patients with mesothelin-expressing solid tumors. The company is headquartered in Cambridge, Massachusetts and was founded in 2015.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X